Effects of vascular novel compoundPivanampeta on modulating function of endothelium against atherosclerosis1

Abstract

Abstract: AIM: To investigate the effects of novel compoundPivanampeta against atherosclerosis.METHODS: The effects ofPivanampeta against atherogenesis were evaluated with rabbits and quails fed with cholesterol-rich diet.RESULTS: Pivanampeta,the novel compound could stimulate the release of nitric oxide,PGI2from endothelium,and had no effect on thelevels of serumlipids.Pivanampeta significantly decreased thelesions of aorta and coronary artery of rabbits,and aorta and brachiocephalic artery of quails.CONCLUSION: Pivanampeta has experimental therapeutic effects against atherosclerosis induced by hypercholesterolemia in rabbits and quails.

Key words: pharmacology, atherosclerosis, hypercholesterolemia, endothelial dysfunction, model, oxidative stress

CLC Number:

WANG Qian, WANG Hai. Effects of vascular novel compoundPivanampeta on modulating function of endothelium against atherosclerosis¹[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(4): 374-380.

References

1 Ross R.Atherosclerosis-an inflammatory disease[J].New Eng J Med,1999;340:115-26
2 Shimokawa H.Primary endothelial dy sfunction:atherosclerosis[J].JMol Cell Cardiol,1999;31:23-37
3 Mehta J,Li D,Mehta JL.Vitamins C and EProlong time to arterial thrombosis in rats[J].J Nutr,1999;129:109-12
4 Chenl,Haught WH,Yang B,et al.Preservation of endogenous antioxidant activity and inhibition oflipidPeroxidation as common mechanisms of antiatherosclerotic effect of vitamin E,lovastatin,and amlodipine[J].J Am Coll Cardiol,1997;30:569-75
5 Salonen RM,Nyyssonen K,Kaikkonen J,et al.Six-year effect of combined vitamin C and E supplementation on atheroscleroticProgression:the antioxidant supplementation in atherosclerosisPrevention(ASAP)study[J].Circulation,2003;107:947-53
6 Stephens NG,Parsons A,SchofieldPM,et al.Randomized controlled trial of vitamin E inPatients with coronary disease:cambridge heart antioxidant study(CHAOS)[J].Lancet,1996;347:781-6
7 Yang RF,Zhao RS,ZhaolZ,et al.An autocatalyzed mannich-type reaction for synthesis of highly substitutedα-aminomethylphosphonates[J].Synthesis,2003;6:887-93
8 王倩,慕邵峰,杨日芳,等.新型α-氨基腈及α-氨基膦酸酯类衍生物对人低密度脂蛋白氧化修饰的影响[J].中国药理学通报,2002;18:468-70
9 王巍,景厚德.鹌鹑动脉粥样硬化模型的建立[J].中华心血管病杂志,1984;12:222-4
10 Stary HC.Evolution andProgression of atheroscleroticlesions in coronary arteries of children and young adults[J].Arteriosclerosis,1989;9:119-32
11 Channon KM,Qian H,George SE.Nitric oxide synthase in atherosclerosis and vascular injury:insights from experimental gene therapy[J].Arterioscler Thromb Vasc Biol,2000;20:1873-81
12luscher TF,Tanner FC,Tschudi MR,et al.Endothelial dysfunction in coronary artery disease[J].Ann Rev Med,1993;44:395-418
13 Boger RH,Bode-Boger SM,Brandes RP,et al.Dietarylarginine reduces theProgression of atherosclerosis in cholesterolfed rabbits:comparison withlovastatin[J].Circulation,1997;96:1282-90
14 Bult H,Herman AG,Matthys KE.Antiatherosclerotic activity of drugs in relation to nitric oxide function[J].Eur JPharmacol,1999;375:157-76
15 Rubbo H.Nitric oxide andPeroxynitrite inlipidPeroxidation[J].Medicina,1998;58:361-6
16 Koh KK,Son JW,Ahn JY,et al.Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemicPatients with coronary artery disease[J].Arterioscler Thromb Vasc Biol,2002;22:e19-23

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[3]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[4]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[5]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[6]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[7]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[8]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[9]	LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
[10]	LUO Mingjie, LIU Runhan, ZHOU Jie, WANG Zhenlei. Comparison of common parameter estimation methods in NONMEM 7.5.1.: A case study of ibuprofen injection in Chinese healthy adult population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 290-298.
[11]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[12]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[13]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[14]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[15]	ZHU Haobin, YUE Hongmei, WU Xingdong, LIU Miaomiao, LI Yating, XU Jinhui. Research progress on the role of the Nrf2 signaling pathway in the complications associated with obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1283-1291.

Effects of vascular novel compoundPivanampeta on modulating function of endothelium against atherosclerosis¹

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments